Literature DB >> 27655414

Engineered Autonomous Human Variable Domains.

Johan Nilvebrant1, Peter M Tessier, Sachdev S Sidhu.   

Abstract

BACKGROUND: The complex multi-chain architecture of antibodies has spurred interest in smaller derivatives that retain specificity but can be more easily produced in bacteria. Domain antibodies consisting of single variable domains are the smallest antibody fragments and have been shown to possess enhanced ability to target epitopes that are difficult to access using multidomain antibodies. However, in contrast to natural camelid antibody domains, human variable domains typically suffer from low stability and high propensity to aggregate.
METHODS: This review summarizes strategies to improve the biophysical properties of heavy chain variable domains from human antibodies with an emphasis on aggregation resistance. Several protein engineering approaches have targeted antibody frameworks and complementarity determining regions to stabilize the native state and prevent aggregation of the denatured state.
CONCLUSION: Recent findings enable the construction of highly diverse libraries enriched in aggregation-resistant variants that are expected to provide binders to diverse antigens. Engineered domain antibodies possess unique advantages in expression, epitope preference and flexibility of formatting over conventional immunoreagents and are a promising class of antibody fragments for biomedical development. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Human domain antibody; aggregation.; antibody engineering; phage display; synthetic antibodies; variable heavy domain

Mesh:

Substances:

Year:  2016        PMID: 27655414      PMCID: PMC5326600          DOI: 10.2174/1381612822666160921143011

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  132 in total

1.  Predicting the solubility of recombinant proteins in Escherichia coli.

Authors:  D L Wilkinson; R G Harrison
Journal:  Biotechnology (N Y)       Date:  1991-05

2.  Supercharging proteins can impart unusual resilience.

Authors:  Michael S Lawrence; Kevin J Phillips; David R Liu
Journal:  J Am Chem Soc       Date:  2007-08-01       Impact factor: 15.419

3.  Protein clefts in molecular recognition and function.

Authors:  R A Laskowski; N M Luscombe; M B Swindells; J M Thornton
Journal:  Protein Sci       Date:  1996-12       Impact factor: 6.725

4.  Rational design of potent domain antibody inhibitors of amyloid fibril assembly.

Authors:  Ali Reza A Ladiwala; Moumita Bhattacharya; Joseph M Perchiacca; Ping Cao; Daniel P Raleigh; Andisheh Abedini; Ann Marie Schmidt; Jobin Varkey; Ralf Langen; Peter M Tessier
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-15       Impact factor: 11.205

5.  Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display.

Authors:  Michael W Traxlmayr; Elisabeth Lobner; Bernhard Antes; Manuela Kainer; Susanne Wiederkum; Christoph Hasenhindl; Gerhard Stadlmayr; Florian Rüker; Max Woisetschläger; Kevin Moulder; Christian Obinger
Journal:  Protein Eng Des Sel       Date:  2012-12-23       Impact factor: 1.650

6.  Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.

Authors:  Joseph M Perchiacca; Ali Reza A Ladiwala; Moumita Bhattacharya; Peter M Tessier
Journal:  Protein Eng Des Sel       Date:  2012-07-27       Impact factor: 1.650

Review 7.  Nanobodies: natural single-domain antibodies.

Authors:  Serge Muyldermans
Journal:  Annu Rev Biochem       Date:  2013-03-13       Impact factor: 23.643

8.  'Camelising' human antibody fragments: NMR studies on VH domains.

Authors:  J Davies; L Riechmann
Journal:  FEBS Lett       Date:  1994-02-21       Impact factor: 4.124

9.  Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold.

Authors:  Akiko Koide; John Wojcik; Ryan N Gilbreth; Robert J Hoey; Shohei Koide
Journal:  J Mol Biol       Date:  2011-12-16       Impact factor: 5.469

Review 10.  Nanobody stabilization of G protein-coupled receptor conformational states.

Authors:  Jan Steyaert; Brian K Kobilka
Journal:  Curr Opin Struct Biol       Date:  2011-07-21       Impact factor: 6.809

View more
  14 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

Review 2.  CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches.

Authors:  Diana Spiegelberg; Johan Nilvebrant
Journal:  Contrast Media Mol Imaging       Date:  2017-06-20       Impact factor: 3.161

Review 3.  Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview.

Authors:  Ellen R Goldman; Jinny L Liu; Dan Zabetakis; George P Anderson
Journal:  Front Immunol       Date:  2017-07-25       Impact factor: 7.561

Review 4.  Phage Display Technique as a Tool for Diagnosis and Antibody Selection for Coronaviruses.

Authors:  Taruna Anand; Nitin Virmani; Bidhan C Bera; Rajesh K Vaid; Medhavi Vashisth; Priyanka Bardajatya; Ashok Kumar; Bhupendra N Tripathi
Journal:  Curr Microbiol       Date:  2021-03-09       Impact factor: 2.188

5.  Exploring the sequence features determining amyloidosis in human antibody light chains.

Authors:  Puneet Rawat; R Prabakaran; Sandeep Kumar; M Michael Gromiha
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

Review 6.  Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.

Authors:  Peter Bannas; Friedrich Koch-Nolte
Journal:  Front Immunol       Date:  2018-11-06       Impact factor: 7.561

7.  Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies.

Authors:  Starlynn C Clarke; Biao Ma; Nathan D Trinklein; Ute Schellenberger; Michael J Osborn; Laure-Hélène Ouisse; Andrew Boudreau; Laura M Davison; Katherine E Harris; Harshad S Ugamraj; Aarti Balasubramani; Kevin H Dang; Brett Jorgensen; Heather Anne N Ogana; Duy T Pham; Payal P Pratap; Preethi Sankaran; Ignacio Anegon; Wim C van Schooten; Marianne Brüggemann; Roland Buelow; Shelley Force Aldred
Journal:  Front Immunol       Date:  2019-01-07       Impact factor: 7.561

8.  Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect.

Authors:  Tao Chen; Xue Liu; Haifeng Hong; Henry Wei
Journal:  J Transl Med       Date:  2020-10-06       Impact factor: 5.531

9.  Bringing the Heavy Chain to Light: Creating a Symmetric, Bivalent IgG-Like Bispecific.

Authors:  Anusuya Ramasubramanian; Rachel Tennyson; Maureen Magnay; Sagar Kathuria; Tara Travaline; Annu Jain; Dana M Lord; Megan Salemi; Caitlin Sullivan; Tristan Magnay; Jiali Hu; Eva Bric-Furlong; Pierrick Rival; Yanfeng Zhou; Dietmar Hoffmann; William Brondyk; Katarina Radošević; Partha S Chowdhury
Journal:  Antibodies (Basel)       Date:  2020-11-06

Review 10.  Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.

Authors:  Emily K Makowski; Lina Wu; Priyanka Gupta; Peter M Tessier
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.